FCCC LOGO Faculty Publications
Rink L , Skorobogatko Y , Kossenkov AV , Belinsky MG , Pajak T , Heinrich MC , Blanke CD , von Mehren M , Ochs MF , Eisenberg B , Godwin AK
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Molecular Cancer Therapeutics. 2009 Aug;8(8) :2172-2182
PMCID: PMC2822341   
Back to previous list
Despite initial efficacy of imatinib mesylate in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. Therefore, clinical management of GIST may benefit from further molecular characterization of tumors before and after imatinib mesylate treatment. As part of a recent phase II trial of neoadjuvant/adjuvant imatinib mesylate treatment for advanced primary and recurrent operable GISTs (Radiation Therapy Oncology Group S0132), gene expression profiling using oligonucleotide microarrays was done on tumor samples obtained before and after imatinib mesylate therapy. Patients were classified according to changes in tumor size after treatment based on computed tomography scan measurements. Gene profiling data were evaluated with Statistical Analysis of Microarrays to identify differentially expressed genes (in pretreatment GIST samples). Based on Statistical Analysis of Microarrays [False Discovery Rate (FDR), 10%], 38 genes were expressed at significantly lower levels in the pretreatment biopsy samples from tumors that significantly responded to 8 to 12 weeks of imatinib mesylate, that is, > 25% tumor reduction. Eighteen of these genes encoded Kruppel-associated box (KRAB) domain containing zinc finger (ZNF) transcriptional repressors. Importantly, 10 KRAB-ZNF genes mapped to a single locus on chromosome 19p, and a subset predicted likely response to imatinib mesylate-based therapy in a naive panel of GIST. Furthermore, we found that modifying expression of genes within this predictive signature can enhance the sensitivity of GIST cells to imatinib mesylate. Using clinical pretreatment biopsy samples from a prospective neoadjuvant phase II trial, we have identified a gene signature that includes KRAB-ZNF 91 subfamily members that may be both predictive of and functionally associated with likely response to short-term imatinib mesylate treatment. [Mol Cancer Ther 2009;8(8):2172-82]
Rink, Lori Skorobogatko, Yuliya Kossenkov, Andrew V. Belinsky, Martin G. Pajak, Thomas Heinrich, Michael C. Blanke, Charles D. von Mehren, Margaret Ochs, Michael F. Eisenberg, Burton Godwin, Andrew K. Amer assoc cancer research Philadelphia 484fm